Nxera Pharma's Neurocrine Partner Clears FDA Hurdle for Alzheimer's Drug Trial
Event summary
- Neurocrine Biosciences received FDA IND acceptance for Phase 2 study of NBI-1117567, an Alzheimer's cognition drug discovered by Nxera Pharma.
- Nxera will receive a $10 million milestone payment from Neurocrine as part of their 2021 collaboration agreement.
- NBI-1117567 is the third muscarinic agonist from Nxera's portfolio to advance to Phase 2 trials.
- Nxera retains development and commercialization rights for M1 agonists in Japan under the agreement.
The big picture
This FDA clearance represents another validation of Nxera's muscarinic agonist strategy, which targets a significant unmet need in Alzheimer's cognition. The $2.6 billion potential milestone package with Neurocrine underscores the high-stakes nature of this collaboration in the competitive neuroscience space. Nxera's ability to retain Japanese rights while leveraging Neurocrine's global reach creates an interesting dual-track commercialization dynamic worth monitoring.
What we're watching
- Pipeline Progress
- How Nxera's NxWave™ platform will continue to produce clinical candidates beyond the current muscarinic agonist portfolio.
- Revenue Recognition
- Whether Nxera can sustain milestone-driven revenue growth as more compounds advance through clinical trials.
- Regional Strategy
- The pace at which Nxera can commercialize M1 agonists in Japan while Neurocrine handles global development.